CorMedix (CRMD) Non Operating Income (2018 - 2026)
CorMedix (CRMD) posted Non Operating Income of -$2.7 million for Q4 2025, down 317.83% sequentially from $1.2 million in Q3 2025, and down 607.74% YoY from $527797.0 in Q4 2024.
CorMedix (CRMD) Non Operating Income (2018 - 2026) Analysis & Trends
CorMedix has reported Non Operating Income for 5 years, with the latest figure at -$2.7 million in Q4 2025.
- Quarterly Non Operating Income fell 607.74% year-over-year to -$2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$124999.0 (down 104.12% YoY) and the FY2025 annual result came in at -$125000.0, down 104.12% from the prior year.
- Non Operating Income retreated to -$2.7 million in Q4 2025 per CRMD's latest filing, from $1.2 million in the prior quarter.
- Over five years, Non Operating Income peaked at $1.2 million in Q3 2025 and troughed at -$2.7 million in Q4 2025.
- A 3-year average of $454364.6 and a median of $764456.0 in 2023 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 140.97% in 2025, down 607.74% in 2025.
- Over 3 years, Non Operating Income stood at $914715.0 in 2023, then sank by 42.3% to $527797.0 in 2024, then slumped by 607.74% to -$2.7 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$2.7 million, $1.2 million, and $805983.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | -4.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.18 Mn |
| Dec 31, 2025 | -2.68 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 805,983.00 |
| Mar 31, 2025 | 518,618.00 |
| Dec 31, 2024 | 527,797.00 |
| Sep 30, 2024 | 510,524.00 |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 843,343.00 |
| Dec 31, 2023 | 914,715.00 |
| Sep 30, 2023 | 722,929.00 |
| Dec 31, 2019 | 71,639.00 |
| Sep 30, 2019 | -93,332.00 |
| Jun 30, 2019 | -219,580.00 |
| Mar 31, 2019 | -244,703.00 |
| Dec 31, 2018 | 10,286.00 |
| Sep 30, 2018 | 5,334.00 |
| Jun 30, 2018 | 15,239.00 |
| Mar 31, 2018 | 3,705.00 |